Essential truths for the care and management of moderate-to-severe psoriasis

Andrew Blauvelt, April W. Armstrong, Gerald G. Krueger

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologies for psoriasis are directed at more specific targets, have a better safety profile, are better tolerated, and are more effective than conventional systemic agents. Despite these advances, many patients with psoriasis remain undertreated, and overall patient satisfaction remains low. The dichotomy between ideal therapeutic outcomes and suboptimal outcomes (which are currently commonplace) is likely largely due to misperceptions about psoriasis and biologic treatments. This article discusses these misperceptions, including the notions that psoriasis is a benign disorder, and that conventional systemic therapies are safer than biologies and adequate for most patients with moderate-to-severe disease. We present practical and evidence-based discussions to refute these misconceptions and provide useful resources for providers and patients that support access to advanced therapies. We believe that biologies represent optimal treatment for most patients with moderate-to-severe psoriasis, and until more effective approaches are generated, these efficacious and target-specific approaches should become the standard of care.

Original languageEnglish (US)
Pages (from-to)805-812
Number of pages8
JournalJournal of Drugs in Dermatology
Volume14
Issue number8
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Psoriasis
Therapeutics
Standard of Care
Patient Satisfaction
Joints
Inflammation
Safety
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Blauvelt, A., Armstrong, A. W., & Krueger, G. G. (2015). Essential truths for the care and management of moderate-to-severe psoriasis. Journal of Drugs in Dermatology, 14(8), 805-812.

Essential truths for the care and management of moderate-to-severe psoriasis. / Blauvelt, Andrew; Armstrong, April W.; Krueger, Gerald G.

In: Journal of Drugs in Dermatology, Vol. 14, No. 8, 01.08.2015, p. 805-812.

Research output: Contribution to journalArticle

Blauvelt, A, Armstrong, AW & Krueger, GG 2015, 'Essential truths for the care and management of moderate-to-severe psoriasis', Journal of Drugs in Dermatology, vol. 14, no. 8, pp. 805-812.
Blauvelt, Andrew ; Armstrong, April W. ; Krueger, Gerald G. / Essential truths for the care and management of moderate-to-severe psoriasis. In: Journal of Drugs in Dermatology. 2015 ; Vol. 14, No. 8. pp. 805-812.
@article{59a14817b1164e86968af891141b0902,
title = "Essential truths for the care and management of moderate-to-severe psoriasis",
abstract = "Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologies for psoriasis are directed at more specific targets, have a better safety profile, are better tolerated, and are more effective than conventional systemic agents. Despite these advances, many patients with psoriasis remain undertreated, and overall patient satisfaction remains low. The dichotomy between ideal therapeutic outcomes and suboptimal outcomes (which are currently commonplace) is likely largely due to misperceptions about psoriasis and biologic treatments. This article discusses these misperceptions, including the notions that psoriasis is a benign disorder, and that conventional systemic therapies are safer than biologies and adequate for most patients with moderate-to-severe disease. We present practical and evidence-based discussions to refute these misconceptions and provide useful resources for providers and patients that support access to advanced therapies. We believe that biologies represent optimal treatment for most patients with moderate-to-severe psoriasis, and until more effective approaches are generated, these efficacious and target-specific approaches should become the standard of care.",
author = "Andrew Blauvelt and Armstrong, {April W.} and Krueger, {Gerald G.}",
year = "2015",
month = "8",
day = "1",
language = "English (US)",
volume = "14",
pages = "805--812",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "8",

}

TY - JOUR

T1 - Essential truths for the care and management of moderate-to-severe psoriasis

AU - Blauvelt, Andrew

AU - Armstrong, April W.

AU - Krueger, Gerald G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologies for psoriasis are directed at more specific targets, have a better safety profile, are better tolerated, and are more effective than conventional systemic agents. Despite these advances, many patients with psoriasis remain undertreated, and overall patient satisfaction remains low. The dichotomy between ideal therapeutic outcomes and suboptimal outcomes (which are currently commonplace) is likely largely due to misperceptions about psoriasis and biologic treatments. This article discusses these misperceptions, including the notions that psoriasis is a benign disorder, and that conventional systemic therapies are safer than biologies and adequate for most patients with moderate-to-severe disease. We present practical and evidence-based discussions to refute these misconceptions and provide useful resources for providers and patients that support access to advanced therapies. We believe that biologies represent optimal treatment for most patients with moderate-to-severe psoriasis, and until more effective approaches are generated, these efficacious and target-specific approaches should become the standard of care.

AB - Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologies for psoriasis are directed at more specific targets, have a better safety profile, are better tolerated, and are more effective than conventional systemic agents. Despite these advances, many patients with psoriasis remain undertreated, and overall patient satisfaction remains low. The dichotomy between ideal therapeutic outcomes and suboptimal outcomes (which are currently commonplace) is likely largely due to misperceptions about psoriasis and biologic treatments. This article discusses these misperceptions, including the notions that psoriasis is a benign disorder, and that conventional systemic therapies are safer than biologies and adequate for most patients with moderate-to-severe disease. We present practical and evidence-based discussions to refute these misconceptions and provide useful resources for providers and patients that support access to advanced therapies. We believe that biologies represent optimal treatment for most patients with moderate-to-severe psoriasis, and until more effective approaches are generated, these efficacious and target-specific approaches should become the standard of care.

UR - http://www.scopus.com/inward/record.url?scp=84956696579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956696579&partnerID=8YFLogxK

M3 - Article

C2 - 26267724

AN - SCOPUS:84956696579

VL - 14

SP - 805

EP - 812

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 8

ER -